综述

硒结合蛋白1作为肿瘤标志物的研究进展

展开
  • 浙江大学 医学院附属第二医院 1.消化内科, 2.肿瘤内科 浙江大学肿瘤研究所, 杭州 310009; 3.浙江省丽水市人民医院消化内科, 丽水 323000
张晨静(1986—), 女, 硕士生;电子信箱: zhangcj2000@sohu.com。

网络出版日期: 2013-02-06

Research progress on selenium binding protein 1 as a novel tumor biomarker

Expand
  • 1.Department of Gastroenterology, 2.Department of Oncology, Institute of Cancer Research, Zhejiang University, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; 3.Department of Gastroenterology, the People´s Hospital of Lishui, Lishui 323000, China

Online published: 2013-02-06

摘要

硒结合蛋白1(SBP1)共价结合于硒参与多种细胞内硒的转运。然而硒是一种重要的微量元素,与肿瘤的发生有密切联系,是一种新型抗肿瘤物质。近年来随着对SBP1研究的深入,发现其不但可作为预后指导个性化治疗策略的一种新型生物标志物,而且有望成为肿瘤治疗的新靶点并提高肿瘤细胞的化疗敏感性,作为一种新型抗肿瘤治疗策略应用于临床。该文旨在探讨SBP1的抗肿瘤机制及其作为潜在肿瘤标志物的研究进展,以期指导临床肿瘤个性化治疗,提高患者的预后效果。

本文引用格式

张晨静, 潘 驰, 潘文胜, 等 . 硒结合蛋白1作为肿瘤标志物的研究进展[J]. 上海交通大学学报(医学版), 2013 , 33(1) : 114 . DOI: 10.3969/j.issn.1674-8115.2013.01.023

Abstract

Selenium binding protein 1 (SBP1) has been shown to bind selenium covalently and is expressed in a variety of tissues and cell lines. Selenium is incorporated into selenoproteins that have a wide range of pleiotropic effects, including its important function in prevention of cancer progression. Recent studies have revealed that SBP1 may not only exert tumor suppressive function, but also become a novel biomarker for predicting prognosis and guiding personalized therapeutic strategies. This paper briefly reviews the studies of SBP1 as a novel biomarker and tumor suppressor in the progression of various cancers.

文章导航

/